Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Down 17.5% in December

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the recipient of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 94,000 shares, a drop of 17.5% from the November 30th total of 114,000 shares. Based on an average daily volume of 90,000 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.6% of the shares of the company are short sold.

Plus Therapeutics Stock Up 7.4 %

PSTV stock traded up $0.08 on Friday, reaching $1.16. 37,204 shares of the company’s stock were exchanged, compared to its average volume of 63,842. The stock has a fifty day moving average of $1.26 and a 200-day moving average of $1.47. The firm has a market cap of $6.84 million, a PE ratio of -0.46 and a beta of 0.70. Plus Therapeutics has a twelve month low of $0.93 and a twelve month high of $2.67.

Wall Street Analyst Weigh In

PSTV has been the topic of several analyst reports. Ascendiant Capital Markets lowered their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Plus Therapeutics in a report on Tuesday, November 26th.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned approximately 9.98% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.